. "1"^^ . "Inhala\u010Dn\u00ED kortikosteroidy" . "Inhala\u010Dn\u00ED kortikosteroidy jsou nej\u00FA\u010Dinn\u011Bj\u0161\u00EDmi preventivn\u00EDmi l\u00E9ky pou\u017E\u00EDvan\u00FDmi u v\u0161ech stup\u0148\u016F perzistuj\u00EDc\u00EDho astmatu. P\u0159\u00EDnos farmakoterapie inhala\u010Dn\u00EDmi kortikosteroidy v doporu\u010Den\u00FDch denn\u00EDch d\u00E1vk\u00E1ch p\u0159eva\u017Euje nad rizikem syst\u00E9mov\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F. V l\u00E9\u010Db\u011B st\u0159edn\u011B t\u011B\u017Ek\u00E9ho a t\u011B\u017Ek\u00E9ho astmatu se preferuj\u00ED inhala\u010Dn\u00ED kortikosteroidy v kombinaci s inhala\u010Dn\u00EDmi b2-agonisty s dlouhodob\u00FDm \u00FA\u010Dinkem. V\u011Bt\u0161ina klinick\u00FDch studi\u00ED uk\u00E1zala, \u017Ee inhala\u010Dn\u00ED kortikosteroidy sni\u017Euj\u00ED frekvenci a z\u00E1va\u017Enost exacerbac\u00ED chronick\u00E9 obstruk\u010Dn\u00ED plicn\u00ED nemoci, zm\u00EDr\u0148uj\u00ED p\u0159\u00EDznaky a zlep\u0161uj\u00ED kvalitu \u017Eivota nemocn\u00FDch, ale neovliv\u0148uj\u00ED postupn\u00E9 zhor\u0161ov\u00E1n\u00ED plicn\u00ED funkce a mortalitu." . "7" . . . . "4" . . "Inhala\u010Dn\u00ED kortikosteroidy"@cs . "Inhala\u010Dn\u00ED kortikosteroidy jsou nej\u00FA\u010Dinn\u011Bj\u0161\u00EDmi preventivn\u00EDmi l\u00E9ky pou\u017E\u00EDvan\u00FDmi u v\u0161ech stup\u0148\u016F perzistuj\u00EDc\u00EDho astmatu. P\u0159\u00EDnos farmakoterapie inhala\u010Dn\u00EDmi kortikosteroidy v doporu\u010Den\u00FDch denn\u00EDch d\u00E1vk\u00E1ch p\u0159eva\u017Euje nad rizikem syst\u00E9mov\u00FDch ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F. V l\u00E9\u010Db\u011B st\u0159edn\u011B t\u011B\u017Ek\u00E9ho a t\u011B\u017Ek\u00E9ho astmatu se preferuj\u00ED inhala\u010Dn\u00ED kortikosteroidy v kombinaci s inhala\u010Dn\u00EDmi b2-agonisty s dlouhodob\u00FDm \u00FA\u010Dinkem. V\u011Bt\u0161ina klinick\u00FDch studi\u00ED uk\u00E1zala, \u017Ee inhala\u010Dn\u00ED kortikosteroidy sni\u017Euj\u00ED frekvenci a z\u00E1va\u017Enost exacerbac\u00ED chronick\u00E9 obstruk\u010Dn\u00ED plicn\u00ED nemoci, zm\u00EDr\u0148uj\u00ED p\u0159\u00EDznaky a zlep\u0161uj\u00ED kvalitu \u017Eivota nemocn\u00FDch, ale neovliv\u0148uj\u00ED postupn\u00E9 zhor\u0161ov\u00E1n\u00ED plicn\u00ED funkce a mortalitu."@cs . . "Inhala\u010Dn\u00ED kortikosteroidy" . . . "Inhalation corticosteroids"@en . "142;144" . "S" . "RIV/00216208:11150/04:00004560" . "3"^^ . "Causa subita" . . "Inhalation; corticosteroids"@en . "RIV/00216208:11150/04:00004560!RIV08-MSM-11150___" . . "[4915E83ECE9B]" . . "Chl\u00E1dek, Jaroslav" . "Inhalation corticosteroids"@en . "568213" . . "11150" . "CZ - \u010Cesk\u00E1 republika" . . "Inhala\u010Dn\u00ED kortikosteroidy"@cs . "Inhalant corticosteroids are the most effective preventive medicine used in all stages of persisting asthma. The benefit of this pharmacotherapy applied in recommended daily doses outweighs the risk of systemic adverse effects. In the treatment of moderately severe and severe asthma, inhalant corticosteroids in combination with the inhalant b2 agonist with long-term effect are preferred. Most clinical studies showed that the inhalant corticosteroids decrease the frequency and severity of exacerbations of the chronic obstructive pulmonary disease, alleviate the signs and improve the quality of patents\u00B4 lives, but do not influence the gradual worsening of lung function and mortality."@en . "1"^^ . "1212-0197" .